Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc (KNSA): 3 pipeline candidates · 2 upcoming catalysts · ~17 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.7 months
D/E 0.36
Lead: Approved
3 candidates
2 upcoming, next in ~196d
0 buys · 28 sells (180d)
A transparent, data-derived signal for Kiniksa Pharmaceuticals International, plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.0B
Cash
$190.0M
Quarterly Burn
$88.6M
Runway
16.7 mo
Revenue
$214.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| Abiprubart | Phase 2 |
| ARCALYST | Approved |
| KPL-387 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$2.04B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 6,823,700 | $328.6M |
| baker bros. advisors lp | 2,826,246 | $136.1M |
| vanguard capital management llc | 2,666,186 | $128.4M |
| tang capital management llc | 2,259,889 | $108.8M |
| vanguard portfolio management llc | 1,766,268 | $85.0M |
| caption management, llc | 999,400 | $48.1M |
| morgan stanley | 997,786 | $48.0M |
| janus henderson group plc | 962,046 | $46.4M |
| d. e. shaw & co., inc. | 959,257 | $46.2M |
| arrowstreet capital, limited partnership | 892,666 | $43.0M |
Showing top 10 of 228 institutional holders of Kiniksa Pharmaceuticals International, plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kiniksa Pharmaceuticals International, plc's pipeline?
Kiniksa Pharmaceuticals International, plc (KNSA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kiniksa Pharmaceuticals International, plc's lead drug candidate?
Kiniksa Pharmaceuticals International, plc's most advanced tracked candidate is Abiprubart (Phase 2) for Sjögren's Disease; Rheumatoid Arthritis (RA).
What is Kiniksa Pharmaceuticals International, plc's next catalyst?
Kiniksa Pharmaceuticals International, plc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: kpl-387" — expected December 31, 2026.
What is Kiniksa Pharmaceuticals International, plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kiniksa Pharmaceuticals International, plc has approximately 16.7 months of cash runway.
What is Kiniksa Pharmaceuticals International, plc's market capitalization?
Kiniksa Pharmaceuticals International, plc's market capitalization is approximately $4.0B.
Get the full picture on Kiniksa Pharmaceuticals International, plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.